MIMS Education

Empagliflozin’s Journey in the Cardio-Renal-Metabolic Continuum: What’s New?

Empagliflozin’s Journey in the Cardio-Renal-Metabolic Continuum: What’s New?

A badge with ribbon in color black 1 Point | An analog clock in color black 2 hours | A black calendar with white triangle in center that has a black exclamation point in the middle 13 Jul 2021 


About this course

In the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial, empagliflozin demonstrated a reduction in cardiovascular events in patients with type 2 diabetes (T2D) and pre-existing cardiovascular disease. This online course covers the evidence base on the use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, in the management of T2D patients with heart failure and chronic kidney disease.

Professor Steven Kahn discusses the data from the EMPA-REG OUTCOME study. Professor Javed Butler, an investigator of the EMPEROR-Reduced trial presents new data on empagliflozin in reducing the risk of cardiovascular death and hospitalisation for heart failure. Professor Darren McGuire provides a commentary and analysis of emerging data of SGLT2 inhibitors from recently completed clinical trials. Professor Katherine Tuttle reviews the therapeutic approaches and recommendations for patients with diabetic kidney disease (DKD), focusing on SGLT2 inhibitors.

1 CPD Point Available

  • Just to complete answering all questions. No passing mark.
  • A certificate can be downloaded upon successful completion. Please use the information on the certificate to claim your CPD points.

Sponsored by